IRVINE, Calif., USA — April 1, 2026
JenaValve Technology, Inc. has announced the U.S. commercial launch of its Trilogy® Transcatheter Heart Valve (THV) System, following recent FDA premarket approval (PMA), marking a major breakthrough in the treatment of symptomatic, severe aortic regurgitation (ssAR). The Trilogy system is the first and only transcatheter device approved in the United States for this specific indication, offering a minimally invasive alternative for patients who are at high or greater risk for surgical aortic valve replacement (SAVR). The first commercial procedures have already been successfully performed at leading U.S. cardiac centers, signaling rapid clinical adoption and strong demand.
First-in-Class Device Addresses Critical Unmet Need
The Trilogy THV System represents a significant advancement in cardiovascular care by providing the first transcatheter treatment option specifically designed for aortic regurgitation, a condition that has historically lacked dedicated minimally invasive therapies. Unlike traditional valve replacement approaches, Trilogy is engineered to overcome the unique anatomical challenges of non-calcified aortic valves, which are common in AR patients.
The system incorporates proprietary radiopaque locator technology, enabling precise anchoring to native valve leaflets without relying on calcification. This innovation ensures secure positioning, improved sealing, and reduced risk of paravalvular regurgitation, which are critical factors in achieving successful clinical outcomes. By addressing these challenges, Trilogy opens new treatment possibilities for a previously underserved patient population.
Minimally Invasive Approach Enhances Patient Outcomes
Advertisement
The Trilogy system is part of the broader transcatheter aortic valve replacement (TAVR) technology, allowing physicians to deliver the valve through a catheter-based procedure rather than open-heart surgery. This minimally invasive approach offers significant benefits, including reduced procedural risk, shorter recovery times, and improved patient comfort, particularly for individuals who are not suitable candidates for surgery.
Clinical experience from the ALIGN-AR trial and early commercial use has demonstrated the system’s ability to deliver consistent and reliable outcomes, reinforcing its potential to become a new standard of care for high-risk AR patients. The device has already been used in over 1,200 procedures in Europe, further validating its safety and effectiveness in real-world clinical settings.
Commercial Launch Expands Access to Advanced Cardiac Care
The U.S. launch of Trilogy marks the beginning of a new phase in JenaValve’s growth strategy, with a focus on expanding access to innovative heart valve therapies across hospitals nationwide. The company has established a dedicated commercial infrastructure to support adoption, training, and distribution, ensuring that patients and healthcare providers can benefit from this cutting-edge technology.
In addition, ongoing clinical studies, including the ARTIST randomized trial, aim to evaluate the potential expansion of Trilogy’s use beyond high-risk patients, potentially broadening its indication and impact in the future. From a regulatory and quality perspective, the device’s development and commercialization underscore the importance of rigorous clinical validation, FDA approval pathways, and compliance with medical device quality standards, including design controls and manufacturing excellence.
Industry Impact and Future Outlook
The introduction of the Trilogy THV System highlights a broader trend toward minimally invasive, patient-centric technologies in cardiovascular medicine, where innovation is focused on improving both clinical outcomes and quality of life. As the prevalence of heart valve disease continues to rise globally, the demand for safe, effective, and less invasive treatment options is expected to grow significantly.
JenaValve’s breakthrough device positions the company at the forefront of next-generation structural heart therapies, with the potential to transform the management of aortic regurgitation and redefine treatment standards. By combining advanced engineering, clinical validation, and regulatory excellence, the Trilogy system represents a major step forward in addressing one of cardiology’s most challenging conditions.
Source: JenaValve press release
